Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog – Page 1511

Humanoid robots are robots that resemble and act like humans. Typically engineered to imitate authentic human expressions, interactions and movements, these robots are often outfitted with an array of cameras, sensors and, more recently, AI and machine learning technologies.

While more humanoid robots are being introduced into the world and making a positive impact in industries like logistics, manufacturing, healthcare and hospitality, their use is still limited, and development costs are high.

That said, the sector is expected to grow. The humanoid robot market is valued at $1.8 billion in 2023, according to research firm MarketsandMarkets, and is predicted to increase to more than $13 billion over the next five years. Fueling that growth and demand will be advanced humanoid robots with greater AI capabilities and human-like features that can take on more duties in the service industry, education and healthcare.

Read more | >

T-Cell Priming Immunotherapies To Provide Broad And Robust, Long-Term Immunity — Prof. Dr. Thomas Rademacher, MD, PhD — CEO & Co-Founder, Emergex Vaccines

Professor Dr. Thomas Rademacher, MD, PhD, is CEO and Co-Founder of Emergex (https://emergexvaccines.com/), a company that has developed a novel nanoparticle-based vaccine technology to deliver synthetic viral fragments via microneedles on a skin-adhesive patch. Emergex’s approach works on the principle of priming immune T-cells, opening the door for the development of universal vaccines against highly mutagenic viruses such as the seasonal flu and covid. T-cell priming offers a superior inoculation strategy over traditional vaccines, which rely on the body’s generation of antibodies and fail to keep up with seasonal mutations.

A serial entrepreneur, Professor Rademacher also serves as Emeritus Professor of Molecular Medicine at University College London (UCL) and is widely considered one of the founders of biotech from the early 1980s (having been involved in many of it’s core disciplines – from recombinant proteins, to monoclonal antibodies, to glycobiology).

Continue reading “Prof. Dr. Thomas Rademacher, MD, PhD — CEO & Co-Founder, Emergex — T-Cell Priming Immunotherapies” | >

Is the Founder and CEO of Torigen Pharmaceuticals (https://www.torigen.com/), a company dedicated to researching and developing novel immuno-oncology products and services specifically for the veterinary market, with a focus on autologous cancer vaccines.

Torigen Pharmaceuticals is a start‑up that resulted from Ashley’s graduate thesis project at the University of Notre Dame, as she was working on her Masters in Engineering, Science and Technology Entrepreneurship in collaboration with Dr. Mark Suckow (https://www.research.uky.edu/staff/ma…). Ashley also received an undergraduate degree in Veterinary Pathology and Pathobiology from University of Connecticut.

Read more | >